Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review)

Wang,Ling; Qian,Jinjun; Yang,Ye; Gu,Chunyan

doi:10.3892/ijo.2021.5253

Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review)

Authors:
- Ling Wang
- Jinjun Qian
- Ye Yang
- Chunyan Gu
View Affiliations

Affiliations: Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210022, P.R. China, School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China
Published online on: August 6, 2021 https://doi.org/10.3892/ijo.2021.5253
Article Number: 73
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The small ubiquitin‑like modifier (SUMO) system serves an important role in the regulation of protein stability and function. SUMOylation sustains the homeostatic equilibrium of protein function in normal tissues and numerous types of tumor. Accumulating evidence has revealed that SUMO enzymes participate in carcinogenesis via a series of complex cellular or extracellular processes. The present review outlines the physiological characteristics of the SUMOylation pathway and provides examples of SUMOylation participation in different cancer types, including in hematological malignancies (leukemia, lymphoma and myeloma). It has been indicated that the SUMO pathway may influence chromosomal instability, cell cycle progression, apoptosis and chemical drug resistance. The present review also discussed the possible relationship between SUMOylation and carcinogenic mechanisms, and evaluated their potential as biomarkers and therapeutic targets in the diagnosis and treatment of hematological malignancies. Developing and investigating inhibitors of SUMO conjugation in the future may offer promising potential as novel therapeutic strategies.

View Figures

View References

1	Deribe YL, Pawson T and Dikic I: Post-translational modifications in signal integration. Nat Struct Mol Biol. 17:666–672. 2010. View Article : Google Scholar
2	Flotho A and Melchior F: Sumoylation: A regulatory protein modification in health and disease. Ann Rev Biochem. 82:357–385. 2013. View Article : Google Scholar
3	Bergink S and Jentsch S: Principles of ubiquitin and SUMO modifications in DNA repair. Nature. 458:461–467. 2009. View Article : Google Scholar
4	Iribarren PA, Di Marzio LA, Berazategui MA, De Gaudenzi JG and Alvarez VE: SUMO polymeric chains are involved in nuclear foci formation and chromatin organization in Trypanosoma brucei procyclic forms. PLoS One. 13:e01935282018. View Article : Google Scholar
5	Hendriks I, Lyon D, Young C, Jensen L, Vertegaal A and Nielsen M: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol. 24:325–336. 2017. View Article : Google Scholar
6	Hendriks I and Vertegaal A: A comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell Biol. 17:581–595. 2016. View Article : Google Scholar
7	Beltrao P, Bork P, Krogan N and van Noort V: Evolution and functional cross-talk of protein post-translational modifications. Mol Syst Biol. 9:7142013. View Article : Google Scholar
8	Zhao X: SUMO-mediated regulation of nuclear functions and signaling processes. Mol Cell. 71:409–418. 2018. View Article : Google Scholar
9	Enserink JM: Sumo and the cellular stress response. Cell Div. 10:42015. View Article : Google Scholar
10	Minguez P, Parca L, Diella F, Mende DR, Kumar R, Helmer-Citterich M, Gavin AC, van Noort V and Bork P: Deciphering a global network of functionally associated post-translational modifications. Mol Syst Biol. 8:5992012. View Article : Google Scholar
11	Han ZJ, Feng YH, Gu BH, Li YM and Chen H: The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol. 52:1081–1094. 2018.
12	Mattoscio D and Chiocca S: SUMO pathway components as possible cancer biomarkers. Future Oncol. 11:1599–1610. 2015. View Article : Google Scholar
13	Xie M, Yu J, Ge S, Huang J and Fan X: SUMOylation homeostasis in tumorigenesis. Cancer Lett. 469:301–309. 2020. View Article : Google Scholar
14	Neuse CJ, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M and Ghobrial IM: Genome instability in multiple myeloma. Leukemia. 34:2887–2897. 2020. View Article : Google Scholar
15	Rajkumar SV and Kumar S: Multiple myeloma current treatment algorithms. Blood Cancer J. 10:942020. View Article : Google Scholar
16	Sha Z and Goldberg AL: Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis. Proc Natl Acad Sci USA. 117:21588–21597. 2020. View Article : Google Scholar
17	Zhao Q, Ma Y, Li Z, Zhang K, Zheng M and Zhang S: The function of SUMOylation and its role in the development of cancer cells under stress conditions: A systematic review. Stem Cells Int. 2020:88357142020. View Article : Google Scholar
18	Li YY, Wang H, Yang XX, Geng HY, Gong G, Kim HJ, Zhou YH and Wu JJ: Small Ubiquitin-Like Modifier 4 (SUMO4) Gene M55V polymorphism and type 2 diabetes mellitus: A Meta-analysis including 6,823 subjects. Front Endocrinol. 8:3032017. View Article : Google Scholar
19	Bohren KM, Nadkarni V, Song JH, Gabbay KH and Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem. 279:27233–27238. 2004. View Article : Google Scholar
20	Liang YC, Lee CC, Yao YL, Lai CC, Schmitz ML and Yang WM: SUMO5, a Novel Poly-SUMO isoform, regulates PML nuclear bodies. Sci Rep. 6:265092016. View Article : Google Scholar
21	Gong L, Li B, Millas S and Yeh ET: Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett. 448:185–189. 1999. View Article : Google Scholar
22	Desterro JM, Rodriguez MS, Kemp GD and Hay RT: Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J Biol Chem. 274:10618–10624. 1999. View Article : Google Scholar
23	Müller S, Hoege C, Pyrowolakis G and Jentsch S: SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol. 2:202–210. 2001. View Article : Google Scholar
24	Johnson ES: Protein modification by SUMO. Ann Rev Biochem. 73:355–382. 2004. View Article : Google Scholar
25	Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH and Hay RT: Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 276:35368–35374. 2001. View Article : Google Scholar
26	Sriramachandran AM, Meyer-Teschendorf K, Pabst S, Ulrich HD, Gehring NH, Hofmann K, Praefcke GJ and Dohmen RJ: Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain. Nat Commun. 10:36782019. View Article : Google Scholar
27	Drag M and Salvesen GS: DeSUMOylating enzymes-SENPs. IUBMB Life. 60:734–742. 2008. View Article : Google Scholar
28	Hecker CM, Rabiller M, Haglund K, Bayer P and Dikic I: Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem. 281:16117–16127. 2006. View Article : Google Scholar
29	Chen Y, Sun XX, Sears RC and Dai MS: Writing and erasing MYC ubiquitination and SUMOylation. Genes Dis. 6:359–371. 2019. View Article : Google Scholar
30	Fan L, Bi T, Wang L and Xiao W: DNA-damage tolerance through PCNA ubiquitination and sumoylation. Biochem J. 477:2655–2677. 2020. View Article : Google Scholar
31	Sriramachandran AM and Dohmen RJ: SUMO-targeted ubiquitin ligases. Biochim Biophys Acta. 1843:75–85. 2014. View Article : Google Scholar
32	Johnson ES, Schwienhorst I, Dohmen RJ and Blobel G: The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 16:5509–5519. 1997. View Article : Google Scholar
33	Lois LM and Lima CD: Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24:439–451. 2005. View Article : Google Scholar
34	Cappadocia L, Pichler A and Lima CD: Structural basis for catalytic activation by the human ZNF451 SUMO E3 ligase. Nat Struct Mol Biol. 22:968–975. 2015. View Article : Google Scholar
35	Eisenhardt N, Chaugule VK, Koidl S, Droescher M, Dogan E, Rettich J, Sutinen P, Imanishi SY, Hofmann K, Palvimo JJ and Pichler A: A new vertebrate SUMO enzyme family reveals insights into SUMO-chain assembly. Nat Struct Mol Biol. 22:959–967. 2015. View Article : Google Scholar
36	Werner A, Flotho A and Melchior F: The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell. 46:287–298. 2012. View Article : Google Scholar
37	Drabikowski K: Ubiquitin and SUMO Modifications in Caenorhabditis elegans stress response. Curr Issues Mol Biol. 35:145–158. 2020. View Article : Google Scholar
38	Lu W, Wang Q, Xu C, Yuan H, Fan Q, Chen B, Cai R, Wu D and Xu M: SUMOylation is essential for Sirt2 tumor-suppressor function in neuroblastoma. Neoplasia. 23:129–139. 2021. View Article : Google Scholar
39	Chanda A, Sarkar A and Bonni S: The SUMO System and TGFβ signaling interplay in regulation of epithelial-mesenchymal transition: Implications for cancer progression. Cancers (Basel). 10:2642018. View Article : Google Scholar
40	Wu G, Xu Y, Ruan N, Li J, Lv Q, Zhang Q, Chen Y, Wang Q, Xia Q and Li Q: Genetic alteration and clinical significance of SUMOylation regulators in multiple cancer types. J Cancer. 11:6823–6833. 2020. View Article : Google Scholar
41	Boulanger M, Paolillo R, Piechaczyk M and Bossis G: The SUMO pathway in Hematomalignancies and their response to therapies. Int J Mol Sci. 20:38952019. View Article : Google Scholar
42	Küppers R: Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 5:251–262. 2005. View Article : Google Scholar
43	Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD Jr, et al: The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 115:2827–2834. 2010. View Article : Google Scholar
44	Chen YC, Hsu WL, Ma YL, Tai DJ and Lee EH: CREB SUMOylation by the E3 ligase PIAS1 enhances spatial memory. J Neurosci. 34:9574–9589. 2014. View Article : Google Scholar
45	Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, et al: Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 124:2081–2090. 2014. View Article : Google Scholar
46	Jiang B, Fan X, Zhang D, Liu H and Fan C: Identifying UBA2 as a proliferation and cell cycle regulator in lung cancer A549 cells. J Cell Biochem. 120:12752–12761. 2019. View Article : Google Scholar
47	Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, et al: NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene. 34:3780–3790. 2015. View Article : Google Scholar
48	Yan S, Li A and Liu Y: CacyBP/SIP inhibits the migration and invasion behaviors of glioblastoma cells through activating Siah1 mediated ubiquitination and degradation of cytoplasmic p27. Cell Biol Int. 42:216–226. 2018. View Article : Google Scholar
49	Imamura Y, Wang PL, Masuno K and Sogawa N: Salivary protein histatin 3 regulates cell proliferation by enhancing p27(Kip1) and heat shock cognate protein 70 ubiquitination. Biochem Biophys Res Commun. 470:269–274. 2016. View Article : Google Scholar
50	Wang L, Bai G and Chen F: Human bone marrow mesenchymal stem cells suppress the proliferation of hepatic stellate cells by inhibiting the ubiquitination of p27. Biochem Cell Biol. 95:628–633. 2017. View Article : Google Scholar
51	Huang X, Tao Y, Gao J, Zhou X, Tang S, Deng C, Lai Z, Lin X, Wang Q and Li T: UBC9 coordinates inflammation affecting development of bladder cancer. Sci Rep. 10:206702020. View Article : Google Scholar
52	He W, Verhees GF, Bhagwat N, Yang Y, Kulkarni DS, Lombardo Z, Lahiri S, Roy P, Zhuo J, Dang B, et al: SUMO fosters assembly and functionality of the MutSγ complex to facilitate meiotic crossing over. Dev Cell. 56:2073–2088.e3. 2021. View Article : Google Scholar
53	Kaul S, Blackford JA Jr, Cho S and Simons SS Jr: Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J Biol Chem. 277:12541–12549. 2002. View Article : Google Scholar
54	Chakrabarti SR, Sood R, Ganguly S, Bohlander S, Shen Z and Nucifora G: Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. Proc Natl Acad Sci USA. 96:7467–7472. 1999. View Article : Google Scholar
55	Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY: Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene. 29:1763–1772. 2010. View Article : Google Scholar
56	Li C, McManus FP, Plutoni C, Pascariu CM, Nelson T, Alberici Delsin LE, Emery G and Thibault P: Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility. Nat Commun. 11:8342020. View Article : Google Scholar
57	Liu B, Tahk S, Yee KM, Fan G and Shuai K: The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science. 330:521–525. 2010. View Article : Google Scholar
58	Kotaja N, Vihinen M, Palvimo JJ and Jänne OA: Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J Biol Chem. 277:17781–17788. 2002. View Article : Google Scholar
59	Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM and Jackson SP: Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature. 462:935–939. 2009. View Article : Google Scholar
60	Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M and Culig Z: PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol. 180:2097–2107. 2012. View Article : Google Scholar
61	Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S and Scaglioni PP: PIAS1 promotes Lymphomagenesis through MYC upregulation. Cell Rep. 15:2266–2278. 2016. View Article : Google Scholar
62	Kadaré G, Toutant M, Formstecher E, Corvol JC, Carnaud M, Boutterin MC and Girault JA: PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J Biol Chem. 278:47434–47440. 2003. View Article : Google Scholar
63	Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, Byers LA, Heymach JV, Girard L, Chiang CM, Teruya-Feldstein J and Scaglioni PP: The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72:2275–2284. 2012. View Article : Google Scholar
64	Schmidt D and Müller S: Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA. 99:2872–2877. 2002. View Article : Google Scholar
65	Moreno-Oñate M, Herrero-Ruiz AM, García-Dominguez M, Cortés-Ledesma F and Ruiz JF: RanBP2-mediated SUMOylation promotes human DNA polymerase lambda nuclear localization and DNA repair. J Mol Biol. 432:3965–3979. 2020. View Article : Google Scholar
66	Wang H, Luo Q, Kang J, Wei Q, Yang Y, Yang D, Liu X, Liu T and Yi P: YTHDF1 aggravates the progression of cervical cancer through m⁶A-mediated up-regulation of RANBP2. Front Oncol. 11:6503832021. View Article : Google Scholar
67	Gilistro E, de Turris V, Damizia M, Verrico A, Moroni S, De Santis R, Rosa A and Lavia P: Importin-β and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function. J Cell Sci. 130:2564–2578. 2017.
68	Maarifi G, Fernandez J, Portilho DM, Boulay A, Dutrieux J, Oddos S, Butler-Browne G, Nisole S and Arhel NJ: RanBP2 regulates the anti-retroviral activity of TRIM5α by SUMOylation at a predicted phosphorylated SUMOylation motif. Commun Biol. 1:1932018. View Article : Google Scholar
69	Kunz K, Piller T and Müller S: SUMO-specific proteases and isopeptidases of the SENP family at a glance. J Cell Sci. 131:jcs2119042018. View Article : Google Scholar
70	Chauhan KM, Chen Y, Chen Y, Liu AT, Sun XX and Dai MS: The SUMO-specific protease SENP1 deSUMOylates p53 and regulates its activity. J Cell Biochem. 122:189–197. 2021. View Article : Google Scholar
71	Bawa-Khalfe T, Yang FM, Ritho J, Lin HK, Cheng J and Yeh ET: SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget. 8:17651–17664. 2017. View Article : Google Scholar
72	Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J and Pandolfi PP: The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature. 455:813–817. 2008. View Article : Google Scholar
73	Sun XX, Chen Y, Su Y, Wang X, Chauhan KM, Liang J, Daniel CJ, Sears RC and Dai MS: SUMO protease SENP1 deSUMOylates and stabilizes c-Myc. Proc Natl Acad Sci USA. 115:10983–10988. 2018. View Article : Google Scholar
74	Huang X, Zuo Y, Wang X, Wu X, Tan H, Fan Q, Dong B, Xue W, Chen GQ and Cheng J: SUMO-specific protease 1 is critical for myeloid-derived suppressor cell development and function. Cancer Res. 79:3891–3902. 2019. View Article : Google Scholar
75	Kanapathipillai M: Treating p53 mutant aggregation-associated cancer. Cancers (Basel). 10:1542018. View Article : Google Scholar
76	Carter S, Bischof O, Dejean A and Vousden KH: C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol. 9:428–435. 2007. View Article : Google Scholar
77	Wu SY and Chiang CM: Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J. 28:1246–1259. 2009. View Article : Google Scholar
78	Ding B, Sun Y and Huang J: Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J Biol Chem. 287:14621–14630. 2012. View Article : Google Scholar
79	Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, et al: Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 129:88–99. 2017. View Article : Google Scholar
80	Amente S, Lavadera ML, Palo GD and Majello B: SUMOactivating SAE1 transcription is positively regulated by Myc. Am J Cancer Res. 2:330–334. 2012.
81	Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 335:348–353. 2012. View Article : Google Scholar
82	Wang WH, Yuan T, Qian MJ, Yan FJ, Yang L, He JQ, Yang B, Lu JJ and Zhu H: Post-translational modification of KRAS: Potential targets for cancer therapy. Acta Pharmacol Sin. 42:1201–1211. 2021. View Article : Google Scholar
83	Uprety D and Adjei AA: KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 89:1020702020. View Article : Google Scholar
84	Moutty MC, Sakin V and Melchior F: Importin α/β mediates nuclear import of individual SUMO E1 subunits and of the holo-enzyme. Mol Biol Cell. 22:652–660. 2011. View Article : Google Scholar
85	Choi BH, Philips MR, Chen Y, Lu L and Dai W: K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion. J Biol Chem. 293:17574–17581. 2018. View Article : Google Scholar
86	Boddy MN, Howe K, Etkin LD, Solomon E and Freemont PS: PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene. 13:971–982. 1996.
87	de Thé H, Pandolfi PP and Chen Z: Acute promyelocytic leukemia: A paradigm for oncoprotein-targeted cure. Cancer Cell. 32:552–560. 2017. View Article : Google Scholar
88	Rao Y, Li R and Zhang D: A drug from poison: How the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci China Life Sci. 56:495–502. 2013. View Article : Google Scholar
89	Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S and de Thé H: A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 7:143–153. 2005. View Article : Google Scholar
90	Stubbe M, Mai J, Paulus C, Stubbe HC, Berscheminski J, Karimi M, Hofmann S, Weber E, Hadian K, Hay R, et al: Viral DNA binding protein SUMOylation promotes PML nuclear body localization next to viral replication centers. mBio. 11:e00049–20. 2020. View Article : Google Scholar
91	El-Asmi F, El-Mchichi B, Maroui MA, Dianoux L and Chelbi-Alix MK: TGF-β induces PML SUMOylation, degradation and PML nuclear body disruption. Cytokine. 120:264–272. 2019. View Article : Google Scholar
92	Sahin U, Ferhi O, Jeanne M, Benhenda S, Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N, de Thé H and Lallemand-Breitenbach V: Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins. J Cell Biol. 204:931–945. 2014. View Article : Google Scholar
93	Li Y, Ma X, Wu W, Chen Z and Meng G: PML nuclear body biogenesis, carcinogenesis, and targeted therapy. Trends Cancer. 6:889–906. 2020. View Article : Google Scholar
94	Ben-Porath I and Weinberg RA: The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 37:961–976. 2005. View Article : Google Scholar
95	Morris EJ and Dyson NJ: Retinoblastoma protein partners. Adv Cancer Res. 82:1–54. 2001. View Article : Google Scholar
96	Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D and Hwang ES: Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 5:187–195. 2006. View Article : Google Scholar
97	Trimarchi JM and Lees JA: Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 3:11–20. 2002. View Article : Google Scholar
98	Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, Grosschedl R and Dejean A: The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell. 22:783–794. 2006. View Article : Google Scholar
99	Yu B, Swatkoski S, Holly A, Lee LC, Giroux V, Lee CS, Hsu D, Smith JL, Yuen G, Yue J, et al: Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci USA. 112:E1724–E1733. 2015. View Article : Google Scholar
100	Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK and Elledge SJ: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 137:835–848. 2009. View Article : Google Scholar
101	Gallipoli P and Huntly BJP: Novel epigenetic therapies in hematological malignancies: Current status and beyond. Semin Cancer Biol. 51:198–210. 2018. View Article : Google Scholar
102	Bryder D, Rossi DJ and Weissman IL: Hematopoietic stem cells: The paradigmatic tissue-specific stem cell. Am J Pathol. 169:338–346. 2006. View Article : Google Scholar
103	Tempé D, Piechaczyk M and Bossis G: SUMO under stress. Biochem Soc Trans. 36:874–878. 2008. View Article : Google Scholar
104	Rajkumar SV: Multiple myeloma. Curr Probl Cancer. 33:7–64. 2009. View Article : Google Scholar
105	Röllig C, Knop S and Bornhäuser M: Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar
106	Susanibar Adaniya SP, Cohen AD and Garfall AL: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. Am J Hematol. 94(Suppl 1): S28–S33. 2019. View Article : Google Scholar
107	Atrash S, Bano K, Harrison B and Abdallah AO: CAR-T treatment for hematological malignancies. J Investig Med. 68:956–964. 2020. View Article : Google Scholar
108	Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B and Kröger N: Development of CAR-T cell therapies for multiple myeloma. Leukemia. 34:2317–2332. 2020. View Article : Google Scholar
109	Feng D and Sun J: Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scand J Immunol. 92:e129102020. View Article : Google Scholar
110	Minnie SA and Hill GR: Immunotherapy of multiple myeloma. J Clin Invest. 130:1565–1575. 2020. View Article : Google Scholar
111	Xu J, Sun HY, Xiao FJ, Wang H, Yang Y, Wang L, Gao CJ, Guo ZK, Wu CT and Wang LS: SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma cells through modulation of NF-κB signaling. Biochem Biophys Res Commun. 460:409–415. 2015. View Article : Google Scholar
112	Xie H, Gu Y, Wang W, Wang X, Ye X, Xin C, Lu M, Reddy BA and Shu P: Silencing of SENP2 in multiple myeloma induces bortezomib resistance by activating NF-κB through the modulation of IκBα sumoylation. Sci Rep. 10:7662020. View Article : Google Scholar
113	Tanaka K and Hirota T: Chromosomal instability: A common feature and a therapeutic target of cancer. Biochim Biophys Acta. 1866:64–75. 2016.
114	McGranahan N, Burrell RA, Endesfelder D, Novelli MR and Swanton C: Cancer chromosomal instability: Therapeutic and diagnostic challenges. EMBO Rep. 13:528–538. 2012. View Article : Google Scholar
115	Giam M and Rancati G: Aneuploidy and chromosomal instability in cancer: A jackpot to chaos. Cell Div. 10:32015. View Article : Google Scholar
116	Dantuma NP and van Attikum H: Spatiotemporal regulation of posttranslational modifications in the DNA damage response. EMBO J. 35:6–23. 2016. View Article : Google Scholar
117	Galanty Y, Belotserkovskaya R, Coates J and Jackson SP: RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair. Genes Dev. 26:1179–1195. 2012. View Article : Google Scholar
118	Biggins S, Bhalla N, Chang A, Smith DL and Murray AW: Genes involved in sister chromatid separation and segregation in the budding yeast Saccharomyces cerevisiae. Genetics. 159:453–470. 2001. View Article : Google Scholar
119	Ohta S, Bukowski-Wills JC, Sanchez-Pulido L, Alves Fde L, Wood L, Chen ZA, Platani M, Fischer L, Hudson DF, Ponting CP, et al: The protein composition of mitotic chromosomes determined using multiclassifier combinatorial proteomics. Cell. 142:810–821. 2010. View Article : Google Scholar
120	Thomas GE, Renjith MR and Manna TK: Kinetochore-microtubule interactions in chromosome segregation: Lessons from yeast and mammalian cells. Biochem J. 474:3559–3577. 2017. View Article : Google Scholar
121	Verdaasdonk JS and Bloom K: Centromeres: Unique chromatin structures that drive chromosome segregation. Nat Rev Mol Cell Biol. 12:320–332. 2011. View Article : Google Scholar
122	Eifler K, Cuijpers SAG, Willemstein E, Raaijmakers JA, El Atmioui D, Ovaa H, Medema RH and Vertegaal AC: SUMO targets the APC/C to regulate transition from metaphase to anaphase. Nat Commun. 9:11192018. View Article : Google Scholar
123	Azuma Y, Arnaoutov A, Anan T and Dasso M: PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes. EMBO J. 24:2172–2182. 2005. View Article : Google Scholar
124	Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, Tahk S, Shuai K, Grosschedl R and van Deursen JM: Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell. 133:103–115. 2008. View Article : Google Scholar
125	Joseph J, Liu ST, Jablonski SA, Yen TJ and Dasso M: The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr Biol. 14:611–617. 2004. View Article : Google Scholar
126	Maison C, Romeo K, Bailly D, Dubarry M, Quivy JP and Almouzni G: The SUMO protease SENP7 is a critical component to ensure HP1 enrichment at pericentric heterochromatin. Nat Struct Mol Biol. 19:458–460. 2012. View Article : Google Scholar
127	Eifler K and Vertegaal ACO: SUMOylation-mediated regulation of cell cycle progression and cancer. Trends Biochem Sci. 40:779–793. 2015. View Article : Google Scholar
128	Schimmel J, Eifler K, Sigurðsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, Kelstrup CD, Francavilla C, Medema RH, Olsen JV and Vertegaal AC: Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell. 53:1053–1066. 2014. View Article : Google Scholar
129	Neyret-Kahn H, Benhamed M, Ye T, Le Gras S, Cossec JC, Lapaquette P, Bischof O, Ouspenskaia M, Dasso M, Seeler J, et al: Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. Genome Res. 23:1563–1579. 2013. View Article : Google Scholar
130	Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP and Dejean A: The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell. 9:769–779. 2005. View Article : Google Scholar
131	Bellail AC, Olson JJ and Hao C: SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun. 5:42342014. View Article : Google Scholar
132	Guo Z, Kanjanapangka J, Liu N, Liu S, Liu C, Wu Z, Wang Y, Loh T, Kowolik C, Jamsen J, et al: Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. Mol Cell. 47:444–456. 2012. View Article : Google Scholar
133	Cheng J, Wang D, Wang Z and Yeh ET: SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol. 24:6021–6028. 2004. View Article : Google Scholar
134	Childs BG, Baker DJ, Kirkland JL, Campisi J and van Deursen JM: Senescence and apoptosis: Dueling or complementary cell fates? EMBO Rep. 15:1139–1153. 2014. View Article : Google Scholar
135	Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V and Lowe SW: Non-cell-autonomous tumor suppression by p53. Cell. 153:449–460. 2013. View Article : Google Scholar
136	Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M and de Thé H: PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence. Proc Natl Acad Sci USA. 112:14278–14283. 2015. View Article : Google Scholar
137	Yates KE, Korbel GA, Shtutman M, Roninson IB and DiMaio D: Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell. 7:609–621. 2008. View Article : Google Scholar
138	Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar
139	Kaufmann SH and Hengartner MO: Programmed cell death: Alive and well in the new millennium. Trends Cell Biol. 11:526–534. 2001. View Article : Google Scholar
140	Zapata JM, Pawlowski K, Haas E, Ware CF, Godzik A and Reed JC: A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem. 276:24242–24252. 2001. View Article : Google Scholar
141	Hockenbery D, Nuñez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:334–336. 1990. View Article : Google Scholar
142	Zamaraev AV, Kopeina GS, Prokhorova EA, Zhivotovsky B and Lavrik IN: Post-translational modification of Caspases: The other side of apoptosis regulation. Trends Cell Biol. 27:322–339. 2017. View Article : Google Scholar
143	Park JH, Lee SW, Yang SW, Yoo HM, Park JM, Seong MW, Ka SH, Oh KH, Jeon YJ and Chung CH: Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage. Nat Commun. 5:54832014. View Article : Google Scholar
144	Xia W, Tian H, Cai X, Kong H, Fu W, Xing W, Wang Y, Zou M, Hu Y and Xu D: Inhibition of SUMO-specific protease 1 induces apoptosis of astroglioma cells by regulating NF-κB/Akt pathways. Gene. 595:175–179. 2016. View Article : Google Scholar
145	Jiang Z, Fan Q, Zhang Z, Zou Y, Cai R, Wang Q, Zuo Y and Cheng J: SENP1 deficiency promotes ER stress-induced apoptosis by increasing XBP1 SUMOylation. Cell Cycle. 11:1118–1122. 2012. View Article : Google Scholar
146	He X, Riceberg J, Pulukuri SM, Grossman S, Shinde V, Shah P, Brownell JE, Dick L, Newcomb J and Bence N: Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation. PLoS One. 10. pp. e01238822015, View Article : Google Scholar
147	Zhang M, Jiang D, Xie X, He Y, Lv M and Jiang X: miR-129-3p inhibits NHEJ pathway by targeting SAE1 and represses gastric cancer progression. Int J Clin Exp Pathol. 12:1539–1547. 2019.
148	Kalamarz ME, Paddibhatla I, Nadar C and Govind S: Sumoylation is tumor-suppressive and confers proliferative quiescence to hematopoietic progenitors in Drosophila melanogaster larvae. Biol Open. 1:161–172. 2012. View Article : Google Scholar
149	Li S, Wang J, Hu G, Aman S, Li B, Li Y, Xia K, Yang Y, Ahmad B, Wang M and Wu H: SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway. Cell Signal. 73:1096862020. View Article : Google Scholar
150	Chang CC, Naik MT, Huang YS, Jeng JC, Liao PH, Kuo HY, Ho CC, Hsieh YL, Lin CH, Huang NJ, et al: Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation. Mol Cell. 42:62–74. 2011. View Article : Google Scholar
151	Santiago A, Godsey AC, Hossain J, Zhao LY and Liao D: Identification of two independent SUMO-interacting motifs in Daxx: Evolutionary conservation from Drosophila to humans and their biochemical functions. Cell Cycle. 8:76–87. 2009. View Article : Google Scholar
152	Wasiak S, Zunino R and McBride HM: Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J Cell Biol. 177:439–450. 2007. View Article : Google Scholar
153	Li P, Jing H, Wang Y, Yuan L, Xiao H and Zheng Q: SUMO modification in apoptosis. J Mol Histol. 52:1–10. 2021. View Article : Google Scholar
154	Menon MB and Dhamija S: Beclin 1 Phosphorylation-at the center of autophagy regulation. Front Cell Dev Biol. 6:1372018. View Article : Google Scholar
155	Sun J, Tai S, Tang L, Yang H, Chen M, Xiao Y, Li X, Zhu Z and Zhou S: Acetylation modification during autophagy and vascular aging. Front Physiol. 12:5982672021. View Article : Google Scholar
156	Son SM, Park SJ, Fernandez-Estevez M and Rubinsztein DC: Autophagy regulation by acetylation-implications for neurodegenerative diseases. Exp Mol Med. 53:30–41. 2021. View Article : Google Scholar
157	Wang R and Wang G: Protein modification and autophagy activation. Adv Exp Med Biol. 1206:237–259. 2019. View Article : Google Scholar
158	Hu B, Zhang Y, Deng T, Gu J, Liu J, Yang H, Xu Y, Yan Y, Yang F, Zhang H, et al: PDPK1 regulates autophagosome biogenesis by binding to PIK3C3. Autophagy. Sep 10–2020.Epub ahead of print. View Article : Google Scholar
159	Liu K, Guo C, Lao Y, Yang J, Chen F, Zhao Y, Yang Y, Yang J and Yi J: A fine-tuning mechanism underlying self-control for autophagy: DeSUMOylation of BECN1 by SENP3. Autophagy. 16:975–990. 2020. View Article : Google Scholar
160	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar
161	Morrison CD, Parvani JG and Schiemann WP: The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett. 341:30–40. 2013. View Article : Google Scholar
162	Lin X, Wang Y, Jiang Y, Xu M, Pang Q, Sun J, Yu Y, Shen Z, Lei R and Xu J: Sumoylation enhances the activity of the TGF-β/SMAD and HIF-1 signaling pathways in keloids. Life Sci. 255:1178592020. View Article : Google Scholar
163	Xu R, Yu S, Zhu D, Huang X, Xu Y, Lao Y, Tian Y, Zhang J, Tang Z, Zhang Z, et al: hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy. Nat Commun. 10:38122019. View Article : Google Scholar
164	Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, et al: The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 7:1815–1823. 2014. View Article : Google Scholar
165	Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD and Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 92:4917–4921. 1995. View Article : Google Scholar
166	Chakrabarti SR, Sood R, Nandi S and Nucifora G: Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. Proc Natl Acad Sci USA. 97:13281–13285. 2000. View Article : Google Scholar
167	Hanson CA, Wood LD and Hiebert SW: Cellular stress triggers TEL nuclear export via two genetically separable pathways. J Cell Biochem. 104:488–498. 2008. View Article : Google Scholar
168	de Thé H, Lavau C, Marchio A, Chomienne C, Degos L and Dejean A: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66:675–684. 1991. View Article : Google Scholar
169	Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B and de Thé H: PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 18:88–98. 2010. View Article : Google Scholar
170	Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S and de Thé H: Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 20:167–174. 2014. View Article : Google Scholar
171	Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ and Hay RT: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 10:538–546. 2008. View Article : Google Scholar
172	Brackett CM and Blagg BS: Current status of SUMOylation inhibitors. Curr Med Chem. 28:3892–3912. 2021. View Article : Google Scholar
173	Yang Y, Xia Z, Wang X, Zhao X, Sheng Z, Ye Y, He G, Zhou L, Zhu H, Xu N and Liang S: Small-molecule inhibitors targeting protein SUMOylation as novel anticancer compounds. Mol Pharmacol. 94:885–894. 2018. View Article : Google Scholar
174	Fukuda I, Ito A, Uramoto M, Saitoh H, Kawasaki H, Osada H and Yoshida M: Kerriamycin B inhibits protein SUMOylation. J Antibiot (Tokyo). 62:221–224. 2009. View Article : Google Scholar
175	Fukuda I, Ito A, Hirai G, Nishimura S, Kawasaki H, Saitoh H, Kimura K, Sodeoka M and Yoshida M: Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 16:133–140. 2009. View Article : Google Scholar
176	Hirohama M, Kumar A, Fukuda I, Matsuoka S, Igarashi Y, Saitoh H, Takagi M, Shin-ya K, Honda K, Kondoh Y, et al: Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem Biol. 8:2635–2642. 2013. View Article : Google Scholar
177	Kayser S, Schlenk RF and Platzbecker U: Management of patients with acute promyelocytic leukemia. Leukemia. 32:1277–1294. 2018. View Article : Google Scholar
178	He X, Riceberg J, Soucy T, Koenig E, Minissale J, Gallery M, Bernard H, Yang X, Liao H, Rabino C, et al: Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 13:1164–1171. 2017. View Article : Google Scholar
179	Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, Bump N, Chau R, Chuang BC, Claiborne C, et al: Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem. 64:2501–2520. 2021. View Article : Google Scholar
180	Lv Z, Yuan L, Atkison JH, Williams KM, Vega R, Sessions EH, Divlianska DB, Davies C, Chen Y and Olsen SK: Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nat Commun. 9:51452018. View Article : Google Scholar
181	Li YJ, Du L, Wang J, Vega R, Lee TD, Miao Y, Aldana-Masangkay G, Samuels ER, Li B, Ouyang SX, et al: Allosteric inhibition of ubiquitin-like modifications by a class of inhibitor of SUMO-activating enzyme. Cell Chem Biol. 26:278–288.e6. 2019. View Article : Google Scholar
182	Takemoto M, Kawamura Y, Hirohama M, Yamaguchi Y, Handa H, Saitoh H, Nakao Y, Kawada M, Khalid K, Koshino H, et al: Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata. J Antibiot (Tokyo). 67:335–338. 2014. View Article : Google Scholar
183	Suzawa M, Miranda DA, Ramos KA, Ang KK, Faivre EJ, Wilson CG, Caboni L, Arkin MR, Kim YS, Fletterick RJ, et al: A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver. Elife. 4:e090032015. View Article : Google Scholar
184	Lu X, Olsen SK, Capili AD, Cisar JS, Lima CD and Tan DS: Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. J Am Chem Soc. 132:1748–1749. 2010. View Article : Google Scholar
185	Berger AJ, Friedlander S, Ghasemi O, Grossman S and Huszar D: Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model. In: Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. pp. 792019
186	Kumar A, Ito A, Hirohama M, Yoshida M and Zhang KY: Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening. J Chem Inf Model. 53:809–820. 2013. View Article : Google Scholar
187	Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, et al: SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 69:1472–1482. 2020. View Article : Google Scholar
188	Kumar A, Ito A, Hirohama M, Yoshida M and Zhang KY: Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping. Bioorg Med Chem Lett. 26:1218–1223. 2016. View Article : Google Scholar
189	Brandt M, Szewczuk LM, Zhang H, Hong X, McCormick PM, Lewis TS, Graham TI, Hung ST, Harper-Jones AD, Kerrigan JJ, et al: Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylation. Assay Drug Dev Technol. 11:308–325. 2013. View Article : Google Scholar
190	Zlotkowski K, Hewitt WM, Sinniah RS, Tropea JE, Needle D, Lountos GT, Barchi JJ Jr, Waugh DS and Schneekloth JS Jr: A Small-molecule microarray approach for the identification of E2 enzyme inhibitors in ubiquitin-like conjugation pathways. SLAS Discov. 22:760–766. 2017.
191	Wiechmann S, Gärtner A, Kniss A, Stengl A, Behrends C, Rogov VV, Rodriguez MS, Dötsch V, Müller S and Ernst A: Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation. J Biol Chem. 292:15340–15351. 2017. View Article : Google Scholar
192	Kim YS, Nagy K, Keyser S and Schneekloth JS Jr: An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation. Chem Biol. 20:604–613. 2013. View Article : Google Scholar
193	Ambaye N, Chen CH, Khanna S, Li YJ and Chen Y: Streptonigrin inhibits SENP1 and reduces the protein level of hypoxia-inducible factor 1α (HIF1α) in cells. Biochemistry. 57:1807–1813. 2018. View Article : Google Scholar
194	Chen Y, Wen D, Huang Z, Huang M, Luo Y, Liu B, Lu H, Wu Y, Peng Y and Zhang J: 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett. 22:6867–6870. 2012. View Article : Google Scholar
195	Qiao Z, Wang W, Wang L, Wen D, Zhao Y, Wang Q, Meng Q, Chen G, Wu Y and Zhou H: Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorg Med Chem Lett. 21:6389–6392. 2011. View Article : Google Scholar
196	Uno M, Koma Y, Ban HS and Nakamura H: Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors. Bioorg Med Chem Lett. 22:5169–5173. 2012. View Article : Google Scholar
197	Xie W, Wang Z, Zhang J, Wang L, Zhao Y and Zhou H: Development and evaluation of a highly reliable assay for SUMO-specific protease inhibitors. Bioorg Med Chem Lett. 26:2124–2128. 2016. View Article : Google Scholar
198	Lindenmann U, Brand M, Gall F, Frasson D, Hunziker L, Kroslakova I, Sievers M and Riedl R: Discovery of a class of potent and selective Non-competitive Sentrin-Specific protease 1 inhibitors. ChemMedChem. 15:675–679. 2020. View Article : Google Scholar
199	Zhao Y, Wang Z, Zhang J and Zhou H: Identification of SENP1 inhibitors through in silico screening and rational drug design. Eur J Med Chem. 122:178–184. 2016. View Article : Google Scholar
200	Wu J, Lei H, Zhang J, Chen X, Tang C, Wang W, Xu H, Xiao W, Gu W and Wu Y: Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget. 7:58995–59005. 2016. View Article : Google Scholar
201	Huang W, He T, Chai C, Yang Y, Zheng Y, Zhou P, Qiao X, Zhang B, Liu Z, Wang J, et al: Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One. 7:e376932012. View Article : Google Scholar
202	Bernstock JD, Ye D, Smith JA, Lee YJ, Gessler FA, Yasgar A, Kouznetsova J, Jadhav A, Wang Z, Pluchino S, et al: Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2. FASEB J. 32:1677–1691. 2018. View Article : Google Scholar
203	Kumar A, Ito A, Takemoto M, Yoshida M and Zhang KY: Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening. J Chem Inf Model. 54:870–880. 2014. View Article : Google Scholar
204	Boggio R, Colombo R, Hay RT, Draetta GF and Chiocca S: A mechanism for inhibiting the SUMO pathway. Mol Cell. 16:549–561. 2004. View Article : Google Scholar
205	Liang Z, Chan HYE, Lee MM and Chan MK: A SUMO1-derived peptide targeting SUMO-interacting motif inhibits α-Synuclein aggregation. Cell Chem Biol. 28:180–190.e6. 2021. View Article : Google Scholar
206	Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM and Deshaies RJ: Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 98:8554–8559. 2001. View Article : Google Scholar
207	Jakobs A, Koehnke J, Himstedt F, Funk M, Korn B, Gaestel M and Niedenthal R: Ubc9 fusion-directed SUMOylation (UFDS): A method to analyze function of protein SUMOylation. Nat Methods. 4:245–250. 2007. View Article : Google Scholar
208	Chen X, Zaro JL and Shen WC: Fusion protein linkers: Property, design and functionality. Adv Drug Deliv Rev. 65:1357–1369. 2013. View Article : Google Scholar